Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Beatriz Rodriguez-Sanchez, Isaac Aranda-Reneo, Juan Oliva-Moreno & Julio Lopez-Bastida. (2021) Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. ClinicoEconomics and Outcomes Research 13, pages 307-334.
Read now
Read now
Steffen Haldrup, Annunziata Lapolla, Jens Gundgaard & Michael L. Wolden. (2020) Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. Journal of Medical Economics 23:3, pages 271-279.
Read now
Read now
Articles from other publishers (7)
Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Crossref
Z. Kevin Lu, Xiaomo Xiong, Taiying Lee, Jun Wu, Jing Yuan & Bin Jiang. (2021) Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Malin Sellbom & Charlotta Nilsson. (2021) Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes. Practical Diabetes 38:2, pages 13-19.
Crossref
Crossref
V. Preumont & M. Buysschaert. (2020) Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials. Diabetes & Metabolism 46:2, pages 83-88.
Crossref
Crossref
Monika Russel-Szymczyk, Vasil Valov, Alexandra Savova & Manoela Manova. (2019) Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. BMC Endocrine Disorders 19:1.
Crossref
Crossref
Marc Evans, Roopa Mehta, Jens Gundgaard & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy 9:5, pages 1919-1930.
Crossref
Crossref
Chantal Mathieu, Pieter Gillard & Katrien Benhalima. (2017) Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology 13:7, pages 385-399.
Crossref
Crossref